Has Alexis Moore received payments from drug or device companies?

Yes. Drug and device makers reported $527 in general payments to Alexis Moore across 27 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alexis Moore did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alexis Moore come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alexis Moore

Psychiatric/Mental Health · San Angelo, TXNPI 1720816861

Payments from drug & device makers

$527in general payments, 2019–2025

Across 27 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alkermes, Inc.$106
AbbVie$91
Lundbeck LLC$57
Vanda Pharmaceuticals Inc.$48
Takeda Pharmaceuticals U.S.A., Inc.$48
Johnson & Johnson$41
plus $136 from 5 others

What the payments were for

Food & beverage$527100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alkermes, Inc.	6	$106
AbbVie	4	$91
Lundbeck LLC	3	$57
Vanda Pharmaceuticals Inc.	2	$48
Takeda Pharmaceuticals U.S.A., Inc.	2	$48
Johnson & Johnson	2	$41
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$36
Otsuka America Pharmaceutical, Inc.	2	$34
E.r. Squibb & Sons, L.L.C.	2	$33
Axsome Therapeutics, Inc.	1	$17
Neurocrine Biosciences, Inc.	1	$16

How this compares

$527 in reported general payments places this provider in the 45th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas →

Medicare billing

Part B allowed, 2024

$3,802

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Clonazepam	20	$337
Duloxetine Hcl	18	$249
Hydroxyzine Hcl	11	$202
Sertraline Hcl	14	$83
Lamotrigine	12	$20
Trazodone Hcl	12	$18

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in San Angelo

Tracy HicksLongview$684K
Natalie TellezHouston$602K
Karah BrashierRichardson$567K
Grant DavisRichardson$360K
Victor IlogEl Paso$167K
Lisa ShamblinGrapevine$163K
Monique GonzalezSan Antonio$126K
Marguerite AddisonWaco$118K
Komi Kokou-AbiRound Rock$88K
Jaime Nelson DensonAustin$88K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →